Piper Sandler Trims Price Target on Perrigo to $35 From $36, Maintains Overweight Rating
Perrigo Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO) and CVRx (CVRX)
Piper Sandler Sticks to Their Buy Rating for Perrigo Company (PRGO)
Perrigo Analyst Ratings
Perrigo's Resilience Amidst Challenges: A Buy Rating Based on Recovery Prospects and Growth Opportunities
Analysts Offer Insights on Healthcare Companies: McKesson (MCK) and Perrigo Company (PRGO)
Piper Sandler Releases a Buy Rating on Perrigo Company (PRGO)
Perrigo's Strategic Divestiture Prompts Buy Rating From Analyst Susan Anderson
Perrigo Analyst Ratings
Perrigo's Game-Changing Opill Gains Groundbreaking CVS Coverage: A Buy Rating Endorsement
Perrigo Analyst Ratings
Piper Sandler Remains a Buy on Perrigo Company (PRGO)
Teva Upgraded at J.P. Morgan on Upcoming Catalysts
JP Morgan Maintains Overweight on Perrigo, Lowers Price Target to $41
Perrigo Analyst Ratings
Piper Sandler Remains a Buy on Perrigo Company (PRGO)
Piper Sandler Issues a Buy Rating on Perrigo Company (PRGO)
Piper Sandler Initiates Coverage On Perrigo With Overweight Rating, Announces Price Target of $37
Perrigo Analyst Ratings
No Data